This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.Find sources: "Brodimoprim" – news · newspapers · books · scholar · JSTOR (August 2014)
Brodimoprim
Clinical data
ATC code
Identifiers
  • 5-[(4-Bromo-3,5-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.054.745 Edit this at Wikidata
Chemical and physical data
FormulaC13H15BrN4O2
Molar mass339.193 g·mol−1
3D model (JSmol)
Melting point225 to 228 °C (437 to 442 °F)
  • Brc1c(OC)cc(cc1OC)Cc2cnc(nc2N)N
  • InChI=1S/C13H15BrN4O2/c1-19-9-4-7(5-10(20-2)11(9)14)3-8-6-17-13(16)18-12(8)15/h4-6H,3H2,1-2H3,(H4,15,16,17,18) checkY
  • Key:BFCRRLMMHNLSCP-UHFFFAOYSA-N checkY
  (verify)

Brodimoprim is a structural derivative of trimethoprim. In brodimoprim, the 4-methoxy group of trimethoprim is replaced with a bromine atom.

As trimethoprim, brodimoprim is a selective inhibitor of bacterial dihydrofolate reductase.[1]

References

  1. ^ Thomson CJ (December 1993). "Trimethoprim and brodimoprim resistance of gram-positive and gram-negative bacteria". Journal of Chemotherapy. 5 (6): 458–64. doi:10.1080/1120009X.1993.11741096. PMID 8195838.
Categories